Notification of Half Year Results

RNS Number : 1205J

Evgen Pharma PLC

03 December 2018

 

For immediate release

3 December 2018

 

Evgen Pharma plc

("Evgen" or "the Company")

Notification of Half Year Results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its interim results for the six months ended 30 September 2018 on Wednesday 12 December 2018.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Wills, Tilly Abraham		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking)		[phone]
WG Partners LLP Nigel Barnes, Claes Spång		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

 

END

 

 

NORBMBFTMBTJBFP